Growth Failure Models

Autoimmune Disease Models
Autoimmune Nephropathy ModelsAsthma ModelsSystemic Lupus Erythematosus (SLE) ModelsSjögren's Syndrome ModelsAutoimmune Dermatoses Models Neuroimmune Disease ModelsInflammatory Bowel Disease (IBD) ModelsRheumatoid Arthritis ModelsImmune Reconstitution Autoimmune Disease Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsAndrogenetic Alopecia (AGA) ModelsMASH ModelsChronic Liver Fibrosis ModelsAcute Liver Injury ModelsChronic Kindey Disease (CKD) ModelsCholestasis ModelsAlcohol-related Liver Disease (ALD) ModelsActue Kindey Disease (AKD) ModelsDiabetes Nephropathy (Diabetic Kidney Disease) ModelsOsteoporosis ModelsSarcopenia ModelsGout/Hyperuricemia ModelsFemale Reproduction Models
Wild Mouse 750
Wild Mouse 750
Rare Disease Mouse Models
Hemophilia ModelsProgressive Familial Intrahepatic Cholestasis ModelsGrowth Failure ModelsAutosomal Dominant Polycystic Kidney Disease (ADPKD)
Neurological Disease Mouse Models
Alzheimer's Disease (AD) ModelsHumanized Alzheimer's Disease (AD) ModelsParkinson's Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) ModelsPain Mouse ModelsDuchenne Muscular Dystrophy (DMD) Models
Oncology Mouse Models
Human Xenograft ModelsDrug ResistanceT-Cell EngagersHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models
Cardiovascular Disease Mouse Models
Heart Failure ModelsHypertension ModelsAtherosclerosis ModelsAdvanced Cardiovascular and Metabolic Complication ModelsHyperlipidemia ModelsHypertropic Cardiomyopathy ModelsStroke ModelsThrombosis Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765

Primary IGF-1 deficiency (PIGFD), also referred to as growth hormone insensitivity syndrome (GHIS), is a disorder characterized by short stature despite normal growth hormone (GH) levels, accompanied by low serum IGF-1 concentrations.

● Genetically Engineered PIGFD Mouse Model

Strain No.

Strain Name

Strain Type

Description

T012670

Igf1-KO

Knockout

Homozygous Igf1-KO mice show embryonic lethality. Heterozygous Igf1-KO mice display reduced body weight and serum IGF-1 level from 3 weeks old, mimicing primary IGF-1 deficiency in human. However, the difference on serum IGF-1 concentration decreases with the increase of the age of mice


Laron syndrome, also termed primary growth hormone insensitivity syndrome (GHIS), is a rare autosomal recessive disorder caused by impaired responsiveness to growth hormone (GH). This condition results from pathogenic mutations in the growth hormone receptor (GHR) gene, leading to disruption of the GH-IGF1 signaling axis.

● Genetically Engineered Laron Syndrome Mouse Model

Strain No.

Strain Name

Strain Type

Description

T060204

Ghr-KO

Knockout

Homozygous Ghr-KO mice display developmental retardation, including significantly reduced body weight and body length compared to those of heterozygous and wild-type mice, which mimics Laron syndrome in human. 


The short stature in children due to growth hormone deficiency is termed growth hormone deficiency (GHD), also known as pituitary dwarfism. Primary growth hormone deficiency, for the majority of cases with no identified cause and only a small proportion having a family history, follows an autosomal recessive inheritance pattern. It involves mutations in the GH1 gene or the growth hormone-releasing hormone receptor (GHRHR) gene, along with defects in genes associated with pituitary gland development.

● Genetically Engineered GHD Mouse Model

Strain No.

Strain Name

Strain Type

Description

T017029

Gh-KO

Knockout

Homozygous Gh-KO mice display developmental retardation, including significantly reduced body weight and body length compared to those of heterozygous and wild-type mice from 3 weeks old. Gh protein and plasma IGF1 are rarely detected in homozygous Gh-KO mice. Insulin level and weight of multiple organs other than the brain are also reduced. Recombinant human GH treatment can paritally attenuate the disease-like phenotype.